A detailed history of Vanguard Group Inc transactions in Incyte Corp stock. As of the latest transaction made, Vanguard Group Inc holds 22,715,821 shares of INCY stock, worth $1.38 Billion. This represents 0.03% of its overall portfolio holdings.

Number of Shares
22,715,821
Previous 22,519,381 0.87%
Holding current value
$1.38 Billion
Previous $1.41 Billion 8.48%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$56.55 - $66.59 $11.1 Million - $13.1 Million
196,440 Added 0.87%
22,715,821 $1.29 Billion
Q4 2023

Feb 14, 2024

BUY
$52.16 - $64.19 $18.8 Million - $23.1 Million
359,962 Added 1.62%
22,519,381 $1.41 Billion
Q3 2023

Nov 14, 2023

BUY
$57.77 - $65.93 $16.7 Million - $19.1 Million
289,882 Added 1.33%
22,159,419 $1.28 Billion
Q2 2023

Aug 14, 2023

BUY
$60.95 - $75.51 $6.76 Million - $8.38 Million
110,916 Added 0.51%
21,869,537 $1.36 Billion
Q1 2023

May 15, 2023

BUY
$70.23 - $86.01 $15.8 Million - $19.3 Million
224,803 Added 1.04%
21,758,621 $1.57 Billion
Q4 2022

Feb 10, 2023

BUY
$67.18 - $84.11 $20.5 Million - $25.7 Million
305,757 Added 1.44%
21,533,818 $1.73 Billion
Q3 2022

Nov 14, 2022

BUY
$66.18 - $82.86 $15.8 Million - $19.8 Million
238,448 Added 1.14%
21,228,061 $1.41 Billion
Q2 2022

Aug 12, 2022

BUY
$66.18 - $83.18 $6.81 Million - $8.56 Million
102,857 Added 0.49%
20,989,613 $1.59 Billion
Q1 2022

May 13, 2022

SELL
$66.02 - $79.71 $3.83 Million - $4.62 Million
-58,003 Reduced 0.28%
20,886,756 $1.66 Billion
Q4 2021

Feb 14, 2022

BUY
$63.34 - $74.11 $5.98 Million - $7 Million
94,422 Added 0.45%
20,944,759 $1.54 Billion
Q3 2021

Nov 12, 2021

BUY
$68.67 - $84.02 $26.1 Million - $31.9 Million
379,803 Added 1.86%
20,850,337 $1.43 Billion
Q2 2021

Aug 13, 2021

BUY
$79.87 - $87.53 $1.63 Billion - $1.79 Billion
20,470,534 New
20,470,534 $1.72 Billion

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $13.5B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.